YZYuanli Zhu

Yuanli Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuanli Zhu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Hongxu Pu

    Department of Orthopedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, 430030 Wuhan, Hubei, China

    2 shared publications
  • Jun Xiao

    Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    2 shared publications
  • Song Li

    Department of Orthopaedics Tongji Medical College Tongji Hospital Huazhong University of Science and Technology 430030 Wuhan China

    2 shared publications
  • Changyu Liu

    Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Danni Luo

    Department of Orthopaedics Tongji Medical College Tongji Hospital Huazhong University of Science and Technology 430030 Wuhan China

    1 shared publication
  • Hao Zhu

    Department of Orthopaedics Tongji Medical College Tongji Hospital Huazhong University of Science and Technology 430030 Wuhan China

    1 shared publication

Latest Publications

  • Open Access

    BCLAF1 Regulates Osteoarthritic Cartilage Degradation Through Interaction with LAMTOR2

    by Song Li, Danni Luo, Yulin Liang, Yi Zou, Hongxu Pu, Meng Zheng, Yuting Wang, Xuying Sun, Hao Zhu, Yuanli Zhu, et al.

    Osteoarthritis (OA) is a progressive degenerative joint disorder with cartilage degradation as the primary cause of joint pain and loss of joint function. B-cell lymphoma-2-associated transcription factor 1 (BCLAF1) is a key regulator of apoptosis and serves as a signal transducer of the NFκB and Hif-1α pathways, both of which are involved in osteoarthritic cartilage degradation. However, whether BCLAF1 contributes to the pathogenesis of OA remains unclear. The present study aims to elucidate the role of BCLAF1 in osteoarthritic cartilage degradation and the underlying mechanisms. We found that BCLAF1 levels were increased in cartilage tissue from OA patients, elder and surgery-induced OA mice, and primary chondrocytes treated with inflammatory cytokines. Knockdown of Bclaf1 in chondrocytes inhibited the expression of catabolic factors and apoptosis rate, while promoting the expression of anabolic factors and enhancing chondrocyte functions such as viability and migration. Conversely, overexpression of Bclaf1 produced the opposite effects. Furthermore, intra-articular injection of adenovirus containing shRNA targeting Bclaf1 attenuated cartilage degradation and osteophytosis in a mouse OA model, while overexpression of BCLAF1 further aggravated cartilage degradation and osteophytosis in vivo. Through immunoprecipitation and protein mass spectrometry, we identified LAMTOR2 as a key mediator of BCLAF1 by regulating the translocation of BCLAF1 into the nucleus. Our findings reveal the critical role and key mechanisms of BCLAF1 in regulating cartilage degradation, representing a novel molecular target for the therapeutic development of OA.


  • Open Access

    Cystathionine-γ-lyase attenuates inflammatory response and pain of osteoarthritis

    by Kang Wei, Zixing Shu, Hongxu Pu, Huanhuan Xu, Song Li, Jun Xiao, Yuanli Zhu, Tian Ma


  • Open Access

    Metformin Attenuates the Inflammatory Response via the Regulation of Synovial M1 Macrophage in Osteoarthritis

    by Meng Zheng, Yuanli Zhu, Kang Wei, Hongxu Pu, Renpeng Peng, Jun Xiao, Changyu Liu, Xuying Sun

    Osteoarthritis (OA), the most common chronic inflammatory joint disease, is characterized by progressive cartilage degeneration, subchondral bone sclerosis, synovitis, and osteophyte formation. Metformin, a hypoglycemic agent used in the treatment of type 2 diabetes, has been evidenced to have anti-inflammatory properties to treat OA. It hampers the M1 polarization of synovial sublining macrophages, which promotes synovitis and exacerbates OA, thus lessening cartilage loss. In this study, metformin prevented the pro-inflammatory cytokines secreted by M1 macrophages, suppressed the inflammatory response of chondrocytes cultured with conditional medium (CM) from M1 macrophages, and mitigated the migration of M1 macrophages induced by interleukin-1ß (IL-1ß)-treated chondrocytes in vitro. In the meantime, metformin reduced the invasion of M1 macrophages in synovial regions brought about by the destabilization of medial meniscus (DMM) surgery in mice, and alleviated cartilage degeneration. Mechanistically, metformin regulated PI3K/AKT and downstream pathways in M1 macrophages. Overall, we demonstrated the therapeutic potential of metformin targeting synovial M1 macrophages in OA.